Welcome to our dedicated page for Perspective Therapeutics news (Ticker: CATX), a resource for investors and traders seeking the latest updates and insights on Perspective Therapeutics stock.
Perspective Therapeutics Inc (CATX) is a clinical-stage radiopharmaceutical company advancing targeted alpha therapies for cancer treatment. This page provides investors and medical professionals with essential updates on the company’s pioneering work in theranostics, which combines therapeutic isotopes with precision imaging diagnostics.
Access real-time announcements including clinical trial milestones, regulatory developments, and strategic partnerships. Our curated news collection offers transparent insights into the company’s progress with 212Pb-based therapies and their applications across oncology specialties.
Key updates cover FDA submissions, peer-reviewed research findings, and manufacturing advancements. Bookmark this page to monitor how CATX’s proprietary targeting peptides and isotope delivery systems are reshaping radiation oncology.
Perspective Therapeutics (NYSE AMERICAN: CATX) will present at the SNMMI Annual Meeting 2024 in Toronto from June 8-11. The company will showcase its clinical and preclinical research, including updates from its Phase 1/2a dose escalation study of [212Pb]VMT-α-NET for neuroendocrine tumors, and preclinical progress on [212Pb]VMT01 for melanoma. Highlights include pooled data from Phase 0 imaging studies and dosimetry evaluations. Additional presentations will cover [212Pb]VMT01 combined with immune checkpoint inhibitors, and [203/212Pb]-PSV-359 targeting FAP in tumor lesions. CEO Thijs Spoor emphasized the company's commitment to advancing cancer treatments.
Perspective Therapeutics (NYSE AMERICAN: CATX) reported fiscal Q1 2024 results and recent business highlights. The company raised $177.2 million through financing and an additional $49.5 million via an ATM agreement. Research and development expenses increased by 127%, while general and administrative expenses decreased by 12%. The net loss for the quarter was $12.3 million, or $0.02 per share, compared to $0.4 million the previous year. The company initiated dosing in its VMT-α-NET and VMT01 clinical trials and entered a collaboration with Bristol Myers Squibb. Perspective's current cash position is $180.6 million, with sufficient funding expected through Q1 2026.
Perspective Therapeutics, Inc. announced participation in various investor conferences in May 2024. The company will showcase advanced cancer treatment applications, providing opportunities for investors to engage with the senior leadership team. Events include discussions on the radiopharmaceutical industry's evolving landscape and fireside chats at prominent conferences.
Perspective Therapeutics, Inc. (NYSE AMERICAN: CATX) will report its first quarter 2024 financial results on May 15, 2024, showcasing its advancements in radiopharmaceutical treatments for various cancers.
Perspective Therapeutics, Inc. (CATX) has been selected by the FDA to participate in the CDRP program for the development of [212Pb]VMT‐α‐NET for the treatment of patients with NETs. The program aims to expedite the CMC development of novel products under IND applications to provide earlier patient access. The investigational product is intended for PRRT-naïve patients with SSTR2-positive unresectable or metastatic NETs and has been granted Fast Track Designation by the FDA based on preclinical data.
FAQ
What is the current stock price of Perspective Therapeutics (CATX)?
What is the market cap of Perspective Therapeutics (CATX)?
